Media headlines about Omeros Corporation (NASDAQ:OMER) have trended positive recently, according to Accern Sentiment. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Omeros Corporation earned a media sentiment score of 0.33 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 12 out of 100, meaning that recent press coverage is very unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- Omeros: It’s Hard Enough To Succeed In Biotech Without False Attacks (seekingalpha.com)
- Omeros’ Pipeline Starting To Get The Recognition It Deserves – Seeking Alpha (seekingalpha.com)
- 3 Biotech Stocks to Buy Now for Up to 270% Growth (moneymorning.com)
- Global Plasminogen Market 2017- Omeros Corporation, Genentech (Roche), Kyowa Hakko Kirin and Boehringer … – Talk Herald (talkherald.com)
- Biotech Movers: BioCryst, Omeros, Radius Health (finance.yahoo.com)
A number of analysts have recently issued reports on the stock. Maxim Group set a $23.00 target price on shares of Omeros Corporation and gave the stock a “buy” rating in a research note on Monday, May 22nd. WBB Securities restated a “buy” rating and set a $75.00 target price on shares of Omeros Corporation in a research note on Thursday, March 30th. Cowen and Company restated an “outperform” rating on shares of Omeros Corporation in a research note on Saturday, June 3rd. Zacks Investment Research cut shares of Omeros Corporation from a “hold” rating to a “sell” rating in a research note on Friday, June 23rd. Finally, Wedbush restated an “outperform” rating and set a $47.00 target price on shares of Omeros Corporation in a research note on Wednesday, May 10th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $32.66.
Shares of Omeros Corporation (NASDAQ OMER) traded up 7.7478% during mid-day trading on Monday, reaching $20.5906. 639,913 shares of the company’s stock traded hands. The firm has a 50-day moving average of $18.46 and a 200 day moving average of $13.78. Omeros Corporation has a 12-month low of $7.20 and a 12-month high of $27.09. The company’s market cap is $904.73 million.
Omeros Corporation (NASDAQ:OMER) last released its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.01. The business had revenue of $12.26 million for the quarter, compared to analysts’ expectations of $13.32 million. Omeros Corporation’s revenue for the quarter was up 65.2% compared to the same quarter last year. During the same period last year, the company earned ($0.54) earnings per share. Equities analysts forecast that Omeros Corporation will post ($1.31) EPS for the current year.
In other news, Director Thomas J. Cable sold 3,000 shares of the stock in a transaction dated Wednesday, April 12th. The shares were sold at an average price of $16.49, for a total value of $49,470.00. Following the sale, the director now directly owns 40,067 shares of the company’s stock, valued at $660,704.83. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Michael A. Jacobsen sold 24,000 shares of the stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $21.20, for a total transaction of $508,800.00. Following the completion of the sale, the vice president now directly owns 2,650 shares in the company, valued at $56,180. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 39,000 shares of company stock worth $857,670. Insiders own 13.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by WKRB News and is the property of of WKRB News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.wkrb13.com/markets/2285754/favorable-news-coverage-very-unlikely-to-affect-omeros-corporation-omer-stock-price.html.
Omeros Corporation Company Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285754/favorable-news-coverage-very-unlikely-to-affect-omeros-corporation-omer-stock-price.html
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.